MedTrace Logo

Biomarkers in Urothelial Cancer Patients Treated With Pembrolizumab

NCT03263039 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2021-08-20

No results posted yet for this study

Summary

In the RESPONDER study, the role of the immune evasive mechanisms combined with genomic characterization will be explored in urothelial cancer patients treated with second-line treatment with pembrolizumab.

Combined profiling of immune and molecular status is novel and may contribute to improved patient stratification and provide rationale for future treatment strategies containing pembrolizumab.

Conditions

  • Transitional Cell Carcinoma of the Bladder
  • Biomarkers

Interventions

DRUG

Pembrolizumab

Pembrolizumab 200 mg Q3W

Sponsors & Collaborators

Principal Investigators

  • M.P.J.K. Lolkema · Erasmus Medical Center

  • A.A.M. van der Veldt · Erasmus Medical Center

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-08-21
Primary Completion
2022-08-19
Completion
2023-08-19

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03263039 on ClinicalTrials.gov